Portfolio news
DCPrime obtains EMA Orphan Medicinal Product approval for AML vaccine
Amsterdam, The Netherlands - DCPrime today announced that the Committee for Orphan Medical Products (COMP) of the European Medicines Agency has issued a positive opinion (more…)
arGEN-X raises mio 27.5 Euro in an oversubscribed series B financing round
Rotterdam, The Netherlands – arGEN-X announced today that it has closed an oversubscribed series B financing round of 27.5 mio Euro (more…)
Galapagos’ GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study
Mechelen, Belgium - Galapagos reports that its JAK1 inhibitor GLPG0634 shows excellent efficacy and safety (more…)
Avantium raises EUR 30 million to advance YXY technology
Amsterdam, The Netherlands – Avantium raises EUR 30 million to advance YXY technology. Read full press release here.
Galapagos initiates second Proof of Mechanism clinical study in GSK alliance
Mechelen, Belgium – Galapagos initiates second Proof of Mechanism clinical study in GSK alliance. Read the full article here.
Avantium spins out its pharmaceutical business
Amsterdam, The Netherlands - Avantium spins out its pharmaceutical business. (more…)
Galapagos discontinues Phase II trial
Mechelen, Belgium – Galapagos announced today that is has stopped its Phase II clinical trial for GLP0259. (more…)
DCPrime initiates its first clinical study in AML patients
Amsterdam, The Netherlands – DCPrime announced today that it initiated a clinical study with its first candidate therapeutic cancer vaccine. (more…)
Abbott and Enanta present positive Phase 2 study data
Boston, USA – Abbott and Enanta present positive 12-week results and 3-day resistance data (more…)
DSMB recommends continuation of Curacyte’s Phase III PHOENIX trial
Munich, Germany – Cyracyte announced today that the PHOENIX Phase III trial of PHP (more…)
Galapagos starts Phase 1b clinical study in cancer patients
Mechelen, Belgium – Galapagos announced today that it starts a Phase 1b clinical study in cancer patients. More information here.
Galapagos reports record revenues and increased profitability in 2010
Mechelen, Belgium - Galapagos reports record revenues and increased profitability in 2010 (more…)
arGEN-X signs discovery and development alliance with Lilly
Rotterdam, The Netherlands - arGEN-X signs discovery and development alliance with Lilly (more…)
Onno van de Stolpe joins Supervisory Board of DCPrime
Amsterdam, The Netherlands – DCPrime is proud to announce that Onno van de Stolpe, CEO of Galapagos, will join (more…)
Teijin Aramid and Avantium enter partnership
Amsterdam, The Netherlands – Teijin Aramid and Avantium entered a partnership to explore green high-performance polymers. See the website of Avantium for more information.
Galapagos starts Phase II clinical trial in rheumatoid arthritis patients
Mechelen, Belgium – Galapagos starts a Phase II clinical study in RA patients. See website for more info.
Evotec AG to acquire majority holding in Develogen AG
Goettingen, Germany - Evotec AG to acquire majority holding in Develogen AG. See website for more information.
Cosmo Pharmaceuticals announces preliminary end result of its tender offer for BioXell
Milan, Italy - Cosmo Pharmaceuticals announces preliminary end result of its tender offer for BioXell. See website for more info.
arGEN-X concludes euro 12.5M financing round
Rotterdam, The Netherlands – agGEN-X announced today that it concluded a 12.5 M Euro round. Thuja Capital also participated in this round. For more information see link.
Johnson & Johnson acquires Omrix Biopharmaceuticals
New York, USA – Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops (more…)
Avantium Completes EUR 18M financing
Amsterdam, The Netherlands – Avantium has completed a EUR 18M financing. Please find the original press release here.
Omrix Biopharmaceuticals receives EMEA approval for EVICEL
New York, USA - OMRIX Biopharmaceuticals, Inc. (“Omrix” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, (more…)
Epicept receives CEPLENE European marketing approval
New York, USA – Epicept has received marketing authorization from the EMEA for EVICEL. Please be referred to the press release.
Curacyte sells subsidiary to The Medicines Company
Munchen, Germany – Curacyte AG today announced that it has sold its wholly owned subsidiary, Curacyte Discovery GmbH based in Leipzig (Germany) to The Medicines Company (NASDAQ: MDCO). Please be referred to the original press release.
Pfizer acquires Coley Pharmaceutical Group
New York, USA – Pfizer announced today that it has acquired Coley Pharmaceutical Group. See the press release here.
Probiodrug AG acquires Ingenium Pharmaceuticals AG
Munchen, Germany – Probiodrug AG has acquired Ingenium Pharmaceuticals AG to form an integrated pharmaceutical company. For more details please find the press release here.
DeveloGen and Teva enter into exclusive license agreement
Goettingen, Germany – DeveloGen and Teva entered into an exclusive license agreement for DeveloGen’s protein kinase B technology for the treatment of cancer. For more information please be referred to the press release.
OMRIX receives FDA approval for its liquid fibrin sealant, Evicel, for use in vascular surgery
New York, USA – OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced that on May 9, 2007, the U.S. Food and Drug Administration, or FDA, approved its supplemental Biologics License Application, or sBLA, to market its liquid fibrin sealant, Evicel(TM), in vascular surgery. (more…)
DeveloGen sells its diabetes drug to Cial Biotechnologies
Goettingen, Germany/Tel-Aviv, Israel — DeveloGen Israel Limited (“DeveloGen”), a wholly owned subsidiary of DeveloGen AG, and Andromeda Biotech Ltd. (“Andromeda”), a newly formed wholly owned subsidiary of Clal Biotechnology Industries Ltd. (“Clal”), today announced that DeveloGen and Andromeda have signed a term sheet for an asset purchase agreement for DeveloGen’s DiaPep277® program for the treatment of type 1 diabetes. (more…)
Elbion AG acquires late-stage product candidate from DrugAbuse Sciences
Leuven, Belgium – Elbion AG Acquires Late-Stage Product Candidate From DrugAbuse Sciences, Inc. For Treatment Of Alcohol Dependence
Elbion NV, a leading European drug discovery and development company, today announced it has acquired a number of product candidates from the French biotechnology company DrugAbuse Sciences. (more…)
Abbott and Enanta form worldwide alliance to develop and commercialize HCV protease inhibitors
Boston, USA – Abbott and Enanta form worldwide alliance to develop and commercialize HCV protease inhibitors. Please find the press release here.
Intercell successfully completes its combined primary and secondary public offering
Vienna, Austria – Intercell successfully completes its combined primary and secondary public offering. Please be referred to the press release.
BioXell listed on the SWX Swiss Exchange
Zurich, Switzerland – BioXell listed on the SWX Swiss Exchange. Please find the press release here.
Omrix Biopharmaceuticals successfully completes IPO on NASDAQ
New York, USA - Omrix Biopharmaceuticals, Inc. announced its initial public offering of 3,437,500 shares of common stock was priced at $10.00 per share. Shares of Omrix’s common stock will trade on the Nasdaq National Market under the symbol “OMRI”. (more…)
Epicept Corporation completes merger with Maxim Pharmaceuticals
Englewood Cliffs, NJ, USA – Epicept Corporation has completed a merger with Maxim Pharmaceuticals. Please find the press release here.
Coley Pharmaceutical Group sets price for initial public offering
Wellesley, MA, USA – Coley Pharmaceutical Group, Inc. today announced the initial public offering of 6,000,000 shares of its common stock at a price of $16.00 per share, (more…)
Galapagos raises EUR20 million with IPO on Euronext Brussels and Euronext Amsterdam
Mechelen, Belgium – Galapagos NV, a genomics-based drug discovery company, announces the details of its capital increase and listing on Euronext Brussels and Euronext Amsterdam. (more…)
Intercell AG prices IPO at EUR5.50 first trading day
Vienna, Austria – Intercell AG prices IPO at EUR5.50 first trading day. See press release here.